Acute leukemias that bear chromosomal translocations at 11q23 possess rearrangements of the MixedLineage Leukemia gene (MLL, HRX, ALL-1). More than 40 different MLL translocations have been reported,but the t(9;11) (MLL-AF9) and the t(4;11) (MLL-AF4) are particularly common. MLL-AF9 is most frequentlyidentified in leukemias diagnosed as AML whereas MLL-AF4 is found solely in leukemias diagnosed as ALLor mixed-lineage leukemia. Patients with MLL-AF4 rearranged leukemias have a poor prognosis. This isparticularly true for infant leukemia where approximately 80% of cases will harbor rearrangement of the MLLgene. We have previously demonstrated that human lymphoblastic leukemias harboring MLLrearrangementspossess a unique gene expression profile that suggests they arise from an earlyhematopoietic progenitor. This approach also identified the receptor tyrosine kinase FLT3 as a potentialtherapeutic target in this disease. Using a murine model system of MLL-AF9 induced AML, we have recentlyidentified a hematopoietic stem cell (HSC) associated gene expression program activated in granulocytemacrophage progenitors (GMP) during their conversion to leukemia stem cells (LSC). In these studies wenoted repression of cebp/a as a component of the MLL-AF9 induced program.
In specific aim 1 we will assesspecific genes found highly expressed in LSC, and perform a high-throughput screen to identify smallmolecules that reverse the LSC program.
In specific aim 2 of this proposal we will work with members ofproject 3 to interrogate the role of cebp/a in MLL-rearranged leukemia.
In specific aim 3 we will work withmembers of projects 1 and 2 to develop a conditional murine model of MLL-AF4 induced leukemia andassess the potential for cooperation with mutant FLT3 alleles during leukemogenesis. Such a model will notonly allow identification of progenitor populations susceptible to MLL-AF4 induced transformation, but alsoprovide a much-needed model for assessment of therapeutics developed in projects 1 and 2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA066996-11A1
Application #
7406276
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Project Start
2007-12-01
Project End
2012-11-30
Budget Start
2007-12-01
Budget End
2009-03-31
Support Year
11
Fiscal Year
2008
Total Cost
$510,801
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hogan, Louise E; Körner, Christian; Hobbs, Kristen et al. (2018) NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Adv 2:1412-1416
Kelly, Rachel S; Lasky-Su, Jessica; Yeung, Sai-Ching J et al. (2018) Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One 13:e0197049
Nakamura, Makoto; Wu, Lizi; Griffin, James D et al. (2018) Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. Leuk Res 72:34-44
Gechijian, Lara N; Buckley, Dennis L; Lawlor, Matthew A et al. (2018) Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat Chem Biol 14:405-412
Chu, S Haihua; Song, Evelyn J; Chabon, Jonathan R et al. (2018) Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Adv 2:2478-2490
Sridhar, Radhakrishnan; Takei, Hisashi; Syed, Riyaz et al. (2018) Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBP?. Molecules 23:
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Wang, Jinhua; Erazo, Tatiana; Ferguson, Fleur M et al. (2018) Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem Biol 13:2438-2448
Fathi, Amir T; Erba, Harry P; Lancet, Jeffrey E et al. (2018) A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132:1125-1133
Cortes, Jorge E; Douglas Smith, B; Wang, Eunice S et al. (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 93:1301-1310

Showing the most recent 10 out of 376 publications